SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Other Events

SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Files An 8-K Other Events

Story continues below

Item 8.01. Other Events

Synthetic Biologics, Inc. (the Company) will be making several
clinical and investor presentations over the next several weeks,
including a presentation at the 2017 Digestive Disease Week
Conference on May 9, 2017, in Chicago, Illinois. In connection
with the presentations, the Company intends to discuss the slide
presentation attached as Exhibit 99.1 hereto, which is
incorporated herein by reference.

The slide presentation attached as Exhibit 99.1 to this Report
includes safe harbor language to the Private Securities
Litigation Reform Act of 1995, as amended, indicating that
certain statements contained in the slide presentation or in the
press release are forward-looking rather than historical.

The Company undertakes no duty or obligation to update or revise
information included in this Report or any of the Exhibits.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1 Synthetic Biologics, Inc. investor presentation dated May 4,
2017


About SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN)

Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).

SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) Recent Trading Information

SYNTHETIC BIOLOGICS, INC. (NYSEMKT:SYN) closed its last trading session down -0.008 at 0.508 with 566,919 shares trading hands.

An ad to help with our costs